Skip to main content
editorial
. 2017 Oct 1;3(4):192–199.

Figure 3.

Figure 3.

(A) Proportion of patients, starting ART in NAP between 2008 and 2014, who had a plasma HIV-1 RNA (viral load, VL) test >6 months and <1 year after ART initiation. (3) Proportion of patients in the NAP program, with plasma HIV-1 RNA (VL) < 50 copies/mL and VL > 1,000 copies/mL, who had repeated viral load tests, and initiated treatment from 2008–2014